El-Sabah Ahmed A, El-Metwally Mohamed T, Abozinadah Najlaa Y
Department of Parasitology, Faculty of Medicine, Al-Azhar University, Nasr City, Cairo, Egypt.
J Egypt Soc Parasitol. 2011 Aug;41(2):307-14.
Egypt leads the world in hepatitis C infection cases. Schistosomiasis and hepatitis C virus (HCV) co-infection is common in Egypt. Hepatitis B (HBsAg) is also encountered. Potassium antimony tartarate was used for schistosomiasis in endemic areas all over the world for more than 50 years, intravenously and was prohibited since late of the last century when the oral drugs were developed. Some authors postulated that schistosomiasis might contribute to persistence of HCV via biological factors. This study compared the prevalence of HCV and HBV among schistosomiasis patients in endemic areas given parenteral or oral route antischistosomiasis. A total of 102 manual workers patients were selected from different areas in Cairo and Gharbia Governorates. They were 82 males and 20 females; their age was ranged between 16-60 years (40 +/- 12). Sheets were filled out on each patient including name, age, sex, history of haematurea or bloody diarrhea, parasitic infection, intravenous injections, blood transfusion, dental care, shaving, previous treatment, and anti-schistosomiasis. They were divided into GI: 50 patients treated IV since 20-30 years ago with ages (49.4 +/- 7.4) and GII: 52 patients treated orally up to 8 years ago with ages (2.2 +/- 7.7). They were subjected to IHAT antischistosomal antibodies, circulating schistosome antigens in urine, HBsAg and HCVAb, the latter was confirmed by PCR for positivity, and Alanin transeferese (ALT). In GI, 42/50 (84%) had HCV compared to 4/52(7.7%) in GII, with statistical significant. HBsAg was detected in a patient. HCV patients showed abnormal liver function. 3/52 received oral treatment showed elevation of liver function (5.8%). 10% (10/50) of GI and 34.6% (18/52) of GII were schistosomal antigen in urine positive.
埃及的丙型肝炎感染病例数位居世界之首。血吸虫病与丙型肝炎病毒（HCV）合并感染在埃及很常见。乙型肝炎（HBsAg）也有发现。酒石酸锑钾在世界各地的流行地区用于治疗血吸虫病达50多年，通过静脉注射给药，自上世纪末口服药物研发出来后被禁用。一些作者推测，血吸虫病可能通过生物学因素导致HCV持续存在。本研究比较了流行地区接受肠外或口服抗血吸虫病治疗的血吸虫病患者中HCV和HBV的患病率。从开罗省和盖勒尤卜省的不同地区共选取了102名体力劳动者患者。其中男性82名，女性20名；年龄在16至60岁之间（40±12岁）。为每位患者填写表格，内容包括姓名、年龄、性别、血尿或血性腹泻病史、寄生虫感染、静脉注射、输血、牙科护理、剃须、既往治疗以及抗血吸虫病治疗情况。他们被分为两组：第一组（GI）：50名患者在20至30年前接受静脉注射治疗，年龄为（49.4±7.4岁）；第二组（GII）：52名患者在8年前接受口服治疗，年龄为（22.2±7.7岁）。对他们进行了间接血凝试验（IHAT）检测抗血吸虫抗体、尿液中循环血吸虫抗原、HBsAg和HCV抗体，后者通过PCR确认阳性，还检测了丙氨酸转氨酶（ALT）。在第一组中，50人中有42人（84%）感染HCV，而在第二组中52人中有4人（7.7%）感染HCV，差异具有统计学意义。在一名患者中检测到HBsAg。HCV患者肝功能异常。接受口服治疗的52人中，有3人（5.8%）肝功能升高。第一组中有10%（50人中的10人）和第二组中有34.6%（52人中的18人）尿液中的血吸虫抗原呈阳性。
